Table 2.

Short stature of SOFT syndrome: prevalence of clinical, radiological, hormonal characteristics and course of treatment with rhGH

	Total	number of missing data
Short stature	42/42 (100%)	0
Median (range) height at investigation (SDS)	- 5.5 (([-8.5]-[-2.8]))	9
Median (range) adult height (cm)	132.5 (103.5–148)	34
Disproportionate short stature	38/42 (90.5%)	0
Small hands and feet	40/40 (100%)	2
Brachydatyly	37/40 (92.5%)	2
Clinodactyly	11/40 (27.5%)	2
Metaphysical irregularity of long bones	24/26 (92%)	16
Hypoplasia of sacrum and pelvis	14/24 (58%)	18
Cone‑shaped epiphyses	27/32 (84%)	10
Delayed ossification of bones	14/25 (56%)	17
Stenosis of craniovertebral junction	4	?
Number of patients treated with rhGH	9/42 (21%)	0
Median (range) serum IGF-I level before rhGH treatment (SDS)	+2 ([-0.5] – [+3])	37
Median (range) age at rhGH onset (years)	6 (2.5–10.1)	33
Median (range) age at rhGH withdrawal (years)	8.7 (5.3–11.6)	33
Median (range) duration of rhGH therapy (years)	2.8 (0.66–6)	33
Reason for stopping rhGH
- No response or weak response on growth	7/9 (78%)	33
- Metabolic cause (diabetes, excessive weight gain)	4/9 (45%)
Median (range) maximum dose of rhGH (µg/kg/d)	67.5 (35–100)	40
Median (range) SDS of height before rhGH therapy	-6.7 ([-8.5]-[-5.5])	38
Median (range) SDS of height after rhGH treatment	-5.95 ([-8.5]-[-4.5])	38
Median (range) maximum serum level of IGF-I under rhGH treatment (SDS)	+3	41

The median was used to summarize the continuous quantitative variables with extreme values (range) in parentheses. The frequencies were used to summarize the qualitative variables and were reported as "No. (%)"

rhGH recombinant human Growth Hormone, SDS standard deviation score